Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 16 Nov 2026
Standard addition

Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study.

A combination therapy approach produced encouraging survival outcomes in patients with difficult-to-treat advanced liver cancer.

This PubMed record examines Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. It reports CONCLUSION: This combination regimen was associated with encouraging outcomes in a selected, high-risk uHCC cohort.

What the study was

Study design
Randomized controlled trial
Population
Human participants
Category
Treatment Innovation
Maturity
Validated
Journal
Journal of hepatocellular carcinoma

Why it surfaced

Randomized controlled trial; conservative rapid-triage score based on PubMed title, publication type, and abstract.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.